MEI Pharma Shares Rise 22% After Positive Data for Zandelisib Trial
30 November 2021 - 3:22PM
Dow Jones News
By Chris Wack
MEI Pharma Inc. shares were up 22%, to $3, after it and Kyowa
Kirin Co. said a Phase 2 study evaluating zandelisib as a single
agent for follicular lymphoma patients who received at least two
prior systemic therapies demonstrated a 70.3% objective response
rate as determined by Independent Review Committee assessment in
the primary efficacy population.
The companies also said 35.2% of patients achieved a complete
response.
The data are currently insufficiently mature to accurately
estimate duration of response. In line with previously reported
data from the Phase 1B study, zandelisib was generally well
tolerated. With 9.4 months, median duration of follow-up in the
total study population, interim data demonstrated a discontinuation
rate due to any drug related adverse event of 9.9%.
Patients enrolled in the study will continue to be followed for
safety and duration of response.
Zandelisib is an investigational selective phosphatidylinositol
3-kinase delta inhibitor in clinical development for the treatment
of B-cell malignancies.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
November 30, 2021 10:07 ET (15:07 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.